Literature DB >> 27480110

Management of Invasive Differentiated Thyroid Cancer.

Iain J Nixon1, Ricard Simo2, Kate Newbold3, Alessandra Rinaldo4, Carlos Suarez5, Luiz P Kowalski6, Carl Silver7, Jatin P Shah8, Alfio Ferlito9.   

Abstract

BACKGROUND: Invasive disease is a poor prognostic factor for patients with differentiated thyroid cancer (DTC). Uncontrolled central neck disease is a common cause of distressing death for patients presenting in this manner. Advances in assessment and management of such cases have led to significant improvements in outcome for this patient group. This article reviews the patterns of invasion and a contemporary approach to investigation and treatment of patients with invasive DTC.
SUMMARY: Aerodigestive tract invasion is reported in around 10% of case series of DTC. Assessment should include not only clinical history and physical examination with endoscopy as indicated, but ultrasound and contrast-enhanced cross-sectional imaging. Further studies including positron emission tomography should be considered, particularly in recurrent cases that are radioactive iodine (RAI) resistant. Both the patient and the extent of disease should be carefully assessed prior to embarking on surgery. The aim of surgery is to resect all gross disease. When minimal visceral invasion is encountered early, "shave" procedures are recommended. In the setting of transmural invasion of the airway or esophagus, however, full thickness excision is required. For intermediate cases in which invasion of the viscera has penetrated the superficial layers but is not evident in the submucosa, opinion is divided. Early reports recommended an aggressive approach. More recently authors have tended to recommend less aggressive resections with postoperative adjuvant therapies. The role of external beam radiotherapy continues to evolve in DTC with support for its use in patients considered to have RAI-resistant tumors.
CONCLUSIONS: Patients with invasive DTC require a multidisciplinary approach to investigation and treatment. With detailed assessment, appropriate surgery, and adjuvant therapy when indicated, this patient group can expect durable control of central neck disease, despite the aggressive nature of their primary tumors.

Entities:  

Mesh:

Year:  2016        PMID: 27480110      PMCID: PMC5118958          DOI: 10.1089/thy.2016.0064

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  72 in total

1.  Letter to the editor regarding: Management of invasive well-differentiated thyroid cancer: An American Head and Neck Society Consensus Statement.

Authors:  Mark A Varvares; Ronald J Walker
Journal:  Head Neck       Date:  2015-12-15       Impact factor: 3.147

2.  Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon.

Authors:  T J Musholt; P B Musholt; M Behrend; R Raab; G F Scheumann; J Klempnauer
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

Review 3.  Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: a systematic review.

Authors:  J-P Jeannon; A A Orabi; G A Bruch; H A Abdalsalam; R Simo
Journal:  Int J Clin Pract       Date:  2009-04       Impact factor: 2.503

4.  Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement.

Authors:  Maisie L Shindo; Salvatore M Caruana; Emad Kandil; Judith C McCaffrey; Lisa A Orloff; John R Porterfield; Ashok Shaha; Jennifer Shin; David Terris; Gregory Randolph
Journal:  Head Neck       Date:  2014-08-23       Impact factor: 3.147

5.  Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  Ann Surg Oncol       Date:  2006-11-11       Impact factor: 5.344

6.  Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.

Authors:  Sin-Ming Chow; Stephen Yau; Chung-Kong Kwan; Patricia C M Poon; Stephen C K Law
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

7.  Locally invasive papillary thyroid carcinoma: 1940-1990.

Authors:  T V McCaffrey; E J Bergstralh; I D Hay
Journal:  Head Neck       Date:  1994 Mar-Apr       Impact factor: 3.147

8.  Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer.

Authors:  Linda M Youngwirth; Mohamed A Adam; Randall P Scheri; Sanziana A Roman; Julie A Sosa
Journal:  Ann Surg Oncol       Date:  2015-09-28       Impact factor: 5.344

9.  Changing trends in well differentiated thyroid carcinoma over eight decades.

Authors:  Iain J Nixon; Ian Ganly; Snehal G Patel; Frank L Palmer; Monica M Whitcher; Rony Ghossein; R Michael Tuttle; Ashok R Shaha; Jatin P Shah
Journal:  Int J Surg       Date:  2012-11-02       Impact factor: 6.071

10.  Clinical practice guideline: improving voice outcomes after thyroid surgery.

Authors:  Sujana S Chandrasekhar; Gregory W Randolph; Michael D Seidman; Richard M Rosenfeld; Peter Angelos; Julie Barkmeier-Kraemer; Michael S Benninger; Joel H Blumin; Gregory Dennis; John Hanks; Megan R Haymart; Richard T Kloos; Brenda Seals; Jerry M Schreibstein; Mack A Thomas; Carolyn Waddington; Barbara Warren; Peter J Robertson
Journal:  Otolaryngol Head Neck Surg       Date:  2013-06       Impact factor: 3.497

View more
  12 in total

1.  Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology.

Authors:  Edwina C Moore; Samuel Zolin; Vikram Krishnamurthy; Judy Jin; Joyce Shin; Eren Berber; Allan Siperstein
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

2.  mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study.

Authors:  S Mazzeo; R Cervelli; R Elisei; G Tarantini; C Cappelli; E Molinaro; D Galleri; L De Napoli; C Comite; R Cioni; P Vitti; D Caramella
Journal:  J Endocrinol Invest       Date:  2018-04-23       Impact factor: 4.256

3.  Prognostic factors in patients with persistent/recurrent differentiated thyroid carcinoma after comprehensive treatment

Authors:  Jianxing Wang; Yao Yao; Yichun Qian; Weiping Yao; Shuai Cheng; Xinyue Yuan; Yuan Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-25

4.  Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?

Authors:  Dauren Adilbay; Avery Yuan; Paul B Romesser; Richard J Wong; Jatin P Shah; Ashok R Shaha; Michael R Tuttle; Snehal Patel; Nancy Y Lee; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2022-05-18       Impact factor: 4.339

5.  Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis.

Authors:  Chenghao Jiang; Tong Cheng; Xucai Zheng; Shikai Hong; Song Liu; Jianjun Liu; Jing Wang; Shengying Wang
Journal:  Cancer Manag Res       Date:  2018-03-09       Impact factor: 3.989

Review 6.  Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.

Authors:  Dario Tumino; Francesco Frasca; Kate Newbold
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-20       Impact factor: 5.555

7.  Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis.

Authors:  Yao Yao; Xinyuan Chen; Hong Yang; Wei Chen; Yichun Qian; Zhongyi Yan; Tian Liao; Weiping Yao; Wenlan Wu; Tonghua Yu; Yun Chen; Yuan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2019-07-19

8.  Thyroid Surgery: Whose Domain Is It?

Authors:  Peter Zbären; Jatin P Shah; Gregory W Randolph; Carl E Silver; Kerry D Olsen; Ashok R Shaha; Mark Zafereo; Luiz P Kowalski; Carlos Suarez; Alvaro Sanabria; Vincent Vander Poorten; Iain Nixon; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2019-08-10       Impact factor: 3.845

9.  FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.

Authors:  Jiapeng Huang; Wei Sun; Zhihong Wang; Chengzhou Lv; Ting Zhang; Dalin Zhang; Wenwu Dong; Liang Shao; Liang He; Xiaoyu Ji; Ping Zhang; Hao Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-28

10.  Tracheal and Cricotracheal Resection With End-to-End Anastomosis for Locally Advanced Thyroid Cancer: A Systematic Review of the Literature on 656 Patients.

Authors:  Cesare Piazza; Davide Lancini; Michele Tomasoni; Anil D'Cruz; Dana M Hartl; Luiz P Kowalski; Gregory W Randolph; Alessandra Rinaldo; Jatin P Shah; Ashok R Shaha; Ricard Simo; Vincent Vander Poorten; Mark Zafereo; Alfio Ferlito
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.